1. Search Result
Search Result
Results for "

PT

" in MedChemExpress (MCE) Product Catalog:

109

Inhibitors & Agonists

1

Fluorescent Dyes

6

Biochemical Assay Reagents

10

Peptides

4

Inhibitory Antibodies

7

Natural
Products

12

Recombinant Proteins

7

Isotope-Labeled Compounds

3

Antibodies

3

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125840
    Belzutifan
    10+ Cited Publications

    PT2977; MK-6482

    HIF/HIF Prolyl-Hydroxylase Cancer
    Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC) .
    Belzutifan
  • HY-13233A
    Talabostat mesylate
    40+ Cited Publications

    Val-boroPro mesylate; PT100 mesylate

    Dipeptidyl Peptidase Inflammation/Immunology Cancer
    Talabostat mesylate (Val-boroPro mesylate; PT100 mesylate) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC50 < 4 nM; Ki = 0.18 nM) and the inhibitor of fibroblast activation protein (FAP) (IC50 = 560 nM), inhibits DPP8/9 (IC50 = 4/11 nM; Ki = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC50 = 310 nM), DPP2, and some other DASH family enzymes. Antineoplastic and hematopoiesis- stimulating activities .
    Talabostat mesylate
  • HY-12867
    PT-2385
    Maximum Cited Publications
    52 Publications Verification

    HIF/HIF Prolyl-Hydroxylase Cancer
    PT-2385 is a selective HIF-2α inhibitor with a Ki of less than 50 nM .
    PT-2385
  • HY-160695

    Ligands for E3 Ligase Molecular Glues Cancer
    PT-179 is an orthogonal Thalidomide (HY-14658) derivative that targets cereblon without causing off-target degradation effects. PT-179 is able to specifically bind CRBN, form a ternary complex with a target protein fused to a zinc finger (ZF) degron, and mediate the degradation of the tagged protein. For example, PT-179 binds to the ubiquitin ligase substrate receptor cereblon by forming a complex with SD40 and efficiently degrades proteins N- or C-terminally fused to SD40 or SD36 (DC50 for eGFP: 4.5 nM and 14.3 nM). PT-179 can be used to develop compact protein degradation tagging platforms .
    PT-179
  • HY-W019870
    Glufosinate ammonium
    1 Publications Verification

    Environmental Pollutants Herbicide Neurological Disease
    Glufosinate ammonium, a phosphinic acid analogue of glutamic acid, is an herbicide which is converted by plant cells into PT (L-phosphinothricin). Glufosinate ammonium exerts neurotoxic activity .
    Glufosinate ammonium
  • HY-108697
    PT2399
    10+ Cited Publications

    HIF/HIF Prolyl-Hydroxylase Cancer
    PT2399 is a potent and selective HIF-2α antagonist, which directly binds to HIF-2α PAS B domain with an IC50 of 6 nM. PT2399 displays potent antitumor activity in vivo .
    PT2399
  • HY-13233

    Val-boroPro; PT100

    Dipeptidyl Peptidase Inflammation/Immunology Cancer
    Talabostat (Val-boroPro; PT100) is an orally active and nonselective dipeptidyl peptidase IV (DPP-IV) inhibitor (IC50 < 4 nM; Ki = 0.18 nM) and the first clinical inhibitor of fibroblast activation protein (FAP) (IC50 = 560 nM), inhibits DPP8/9 (IC50 = 4/11 nM; Ki = 1.5/0.76 nM), quiescent cell proline dipeptidase (QPP) (IC50 = 310 nM), DPP2, and some other DASH family enzymes. Antineoplastic and hematopoiesis- stimulating activities .
    Talabostat
  • HY-18678A
    Bremelanotide Acetate
    1 Publications Verification

    PT-141 Acetate

    Melanocortin Receptor Metabolic Disease
    Bremelanotide (PT-141) Acetate is a melanocortin receptor agonist. Bremelanotide Acetate can activate MC4R and increases dopamine release. Bremelanotide Acetate induces appetitive sexual behaviors, female mounting behavior, and repetitive self-grooming. Bremelanotide Acetate can be used for the research of hypoactive sexual desire disorders .
    Bremelanotide Acetate
  • HY-18678
    Bremelanotide
    1 Publications Verification

    PT-141

    Melanocortin Receptor Neurological Disease Metabolic Disease
    Bremelanotide (PT-141) is a melanocortin receptor agonist. Bremelanotide can activate MC4R and increases dopamine release. Bremelanotide induces appetitive sexual behaviors, female mounting behavior, and repetitive self-grooming. Bremelanotide can be used for the research of hypoactive sexual desire disorders .
    Bremelanotide
  • HY-10824

    PT523

    Antifolate Dihydrofolate reductase (DHFR) Cancer
    Talotrexin (PT523), an analog of Aminopterin (HY-14518), is a nonpolyglutamatable classic antifolate. Talotrexin is a RFC (reduced folate carrier) specific inhibitor and selectively inhibits RFC transport. Talotrexin shows antitumor activity by targeting DHFR to inhibit tumor growth .
    Talotrexin
  • HY-153166

    PROTACs GSK-3 Tau Protein Neurological Disease
    PT-65 is a GSK3α and GSK3β PROTAC degrader with DC50 values of 28.3 nM and 34.2 nM, respectively. PT-65 inhibits excessive tau phosphorylation mediated by GSK3β, Aβ and Okadaic acid (HY-N6785). PT-65 is applicable for the research of Alzheimer's disease .
    PT-65
  • HY-16339
    N3PT
    2 Publications Verification

    N3-pyridyl thiamine

    Transketolase Cancer
    N3PT (N3-pyridyl thiamine) is a potent and selective transketolase inhibitor. N3PT is pyrophosphorylated and then binds to transketolase with an Kd value of 22 nM (Apo-TK, transketolase lacking bound thiamine) .
    N3PT
  • HY-156562A
    5-PT formic
    1 Publications Verification

    5-PropargyltryPTamide formic

    Drug Derivative Inflammation/Immunology
    5-PT (5-Propargyltryptamide) formic is an alkyne-functionalized 5-HT (HY-B1473A) derivative and serotonylation substrate, taken up by living cells. 5-PT formic conjugated to a biotin enables identification of serotonylated proteins via copper-click chemistry and mass spectrometry. 5-PT formic labels and isolates serotonylated cells in alveolar epithelial cells for proteomic analysis. 5-PT formic can be used for the research of bronchopulmonary dysplasia .
    5-PT formic
  • HY-Y0286

    Hartshorn salt, 99%

    Environmental Pollutants Biochemical Assay Reagents Others
    Ammonium carbonate (Ammonium carbonate), 99% is a solid amino compound that functions as a buffer, pH regulator, pore-forming agent, and electrocatalytic oxidation substrate. Ammonium carbonate, 99% is a GRAS-grade direct food additive with no restricted daily intake specified by FAO/WHO, and it shows no acute skin toxicity, clinical signs of toxicity, or effects on body weight in rats. Ammonium carbonate, 99% undergoes electrocatalytic oxidation in alkaline solutions with a Pt/C catalyst (carbonate adsorption interferes with activity). Ammonium carbonate, 99% can serve as a fuel for low-temperature polymer fuel cells and anion exchange membrane fuel cells (with performance superior to pure ammonia), and can also form pores in the carrier-free Pt cathode catalyst layer after low-temperature decomposition, thereby enhancing catalyst activity under low-humidity conditions and the performance of proton exchange membrane fuel cells .
    Ammonium carbonate, 99%
  • HY-170872

    PROTACs DNA/RNA Synthesis Cancer
    PT-129 is a G3BP1/G3BP2 PROTAC degrader. PT-129 inhibits the formation of stress granules, disassembles pre-existing stress granules, disrupts stress granule-mediated ATF4 trafficking via migratory exocytosis, and suppresses cancer cell proliferation. PT-129 is applicable to the research of lung cancer and melanoma .
    PT-129
  • HY-164782

    HDAC Neurological Disease Metabolic Disease Cancer
    PT3 is a selective inhibitor of HDAC3 with an IC50 value of 0.25 μM. PT3 exhibits good brain penetration ability and bioavailability upon oral administration. PT3 can be used in the research of Alzheimer’s disease .
    PT3
  • HY-167832

    JNK SGK ROCK Tau Protein MMP DNA/RNA Synthesis Pyruvate Kinase NF-κB COX NO Synthase Reactive Oxygen Species (ROS) Neurological Disease Cancer
    PT109 is an orally active, blood-brain barrier permeable multi-kinase inhibitor. By inhibiting PTBP1, PT109 promotes the switch of pyruvate kinase isoform from PKM2 to PKM1, thereby effectively inhibiting the proliferation and migration of glioblastoma multiforme and inducing its reprogramming into oligodendrocytes. PT109 also targets and regulates key signaling molecules such as JNK, SGK1, GSK3β to exert neuroprotective effects including promoting neurogenesis, inducing synapse formation and alleviating neuroinflammation. In Alzheimer's disease models, PT109 exhibits significant efficacy in improving spatial learning ability, along with excellent in vivo pharmacokinetic properties. PT109 can be used to investigate metabolic reprogramming of glioblastoma multiforme and neuroprotective mechanisms of Alzheimer's disease .
    PT109
  • HY-109146

    PT-112

    Apoptosis DNA Alkylator/Crosslinker Cancer
    Imifoplatin (PT-112) is a platinum-based active molecule and a member of the phosphaplatins family. Imifoplatin can induce Apoptosis and exhibits antitumor activity .
    Imifoplatin
  • HY-114842
    TDRL-551
    1 Publications Verification

    DNA/RNA Synthesis Cancer
    TDRL-551 is a potent replication protein A (RPA) inhibitor (IC50 = 18 µM). TDRL-551 inhibits RPA-DNA interaction and increases the anti-cancer efficacy of Platinum (Pt)-based chemotherapy. TDRL-551 can be used for the research of cancer, such as non-small cell lung cancer (NSCLC) .
    TDRL-551
  • HY-P9995

    JNJ-63733657

    Tau Protein Neurological Disease
    Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217). Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease .
    Posdinemab
  • HY-163087

    Orphan GPCR Neurological Disease Metabolic Disease
    PT-91 is an agonist of GPR27. PT-91 exhibits high metabolic stability and brain exposure in mice .
    PT-91
  • HY-156562

    5-PropargyltryPTamide

    Drug Derivative Inflammation/Immunology
    5-PT (5-Propargyltryptamide) is an alkyne-functionalized 5-HT (HY-B1473A) derivative and serotonylation substrate, taken up by living cells. 5-PT conjugated to a biotin enables identification of serotonylated proteins via copper-click chemistry and mass spectrometry. 5-PT labels and isolates serotonylated cells in alveolar epithelial cells for proteomic analysis. 5-PT can be used for the research of bronchopulmonary dysplasia .
    5-PT
  • HY-125558

    ORG-34517

    Glucocorticoid Receptor Neurological Disease
    PT150 (ORG-34517) is a competitive and orally active glucocorticoid receptor antagonist. PT150 shows neuroprotective effects. PT150 has the potential for the research of Parkinson’s disease .
    PT150
  • HY-Y0287AS

    Isotope-Labeled Compounds Others
    Calcium carbonate,99.8%,PT- 13C is the 13C labeled Calcium carbonate,99.95-100.05%,PT .
    Calcium carbonate,99.8%,PT-13c
  • HY-W781133

    cis-[PT(NH3)2N1-pyridineCl]Cl

    DNA Alkylator/Crosslinker Cancer
    cDPCP (cis-[Pt(NH3)2(N1-pyridine)Cl]Cl) is a DNA crosslinking agent and also a substrate for OCT1 and OCT2. DPCP exhibits anticancer activity and can improve the survival rate of sarcoma-180 mice. cDPCP is suitable for the research of colorectal cancer and cancers with appropriate cation transporters .
    cDPCP
  • HY-W007865
    4-Bromo-2-methoxyphenol
    1 Publications Verification

    4-Bromoguaiacol

    Drug Intermediate Others
    4-Bromo-2-methoxyphenol is a pharmaceutical intermediate that can be used for the synthesis of 2- (o-Tolyloxy) -5-hexylphenol (PT-70) .
    4-Bromo-2-methoxyphenol
  • HY-75070

    Biochemical Assay Reagents Others
    (+)-1-(1-Naphthyl)ethylamine ((+)-1-(1-NEA)) is a chiral modifier used to introduce enantioselectivity in catalytic hydrogenation reactions. 1-NEA can undergo H-D exchange with D2 in solution to form N?D bonds. That is, 1-NEA can complete Pt surface adsorption and protonation through amine N atoms, indicating that NEA molecules have the potential to impart enantioselectivity to Pt hydrogenation catalysts .
    (+)-1-(1-Naphthyl)ethylamine
  • HY-W017831

    Biochemical Assay Reagents Drug Intermediate Others
    2-Maleimido acetic acid is a maleimide-containing carboxylic acid ligand used to prepare Pt(IV) complexes capable of undergoing Diels-Alder reaction with furan derivatives for drug targeting and delivery applications .
    2-Maleimido acetic acid
  • HY-168022
    CAM2602
    1 Publications Verification

    Aurora Kinase Cancer
    CAM2602 is an orally active Aurora A-TPX2 protein−protein interaction inhibitor with a human Kd of 19 nM for Aurora A. CAM2602 increases the proportion of PH3 positive cells while reducing P-T288 Aurora A levels. CAM2602 arrests tumor xenograft growth in mice. CAM2602 can be used for the research of cancer, such as acute T cell leukemia .
    CAM2602
  • HY-162133

    STING Apoptosis IKK IFNAR NF-κB Cancer
    MSA-2-Pt, platinum salt-modified MSA-2 (HY-136927), is a STING agonist. MSA-2-Pt inducing cell
    death by platinum and activating the STING pathway by MSA-2. MSA-2-Pt direct activates STING pathway, induces phosphorylation of TBK1, IRF3, and NF-κB p65. MSA-2-Pt enhances tumor infiltration of CD4 + and CD8 + T cells, and induces tumor cell death and apoptosis in mouse colon carcinoma and melanoma models .
    MSA-2-Pt
  • HY-103239

    AMPK Cardiovascular Disease Metabolic Disease
    PT1 is an AMPKα1 activator that directly activates the inactive truncated forms of AMPKα1 monomers .
    PT1
  • HY-W543137

    G-quadruplex DNA/RNA Synthesis Mitosis Cancer
    Pt-ttpy, a metallo-organic complex and potent G-quadruplex ligand, effectively triggers substantial telomere-related DNA damage in cancer cells by inhibiting telomerase and/or telomere functions, while also causing various chromatin abnormalities during mitosis, such as chromatin bridges, ultrafine bridges (UFBs), and double-stranded breaks (DSBs).
    PT-ttpy
  • HY-113326

    trans-Phytoene

    Reactive Oxygen Species (ROS) Cancer
    Phytoene (trans-Phytoene) is a carotene pigment. Phytoene is the precursor of all carotenoids. Phytoene is the predominant PT isomer in most carotenogenic organisms. Phytoene can delay the skin tumors appearance and reduce their number in mice that are induced the tumors with UV-B light. Phytoene leads to protection against oxidative stress and malignant transformation. Phytoene inhibits the proliferation of breast cancer cells .
    Phytoene
  • HY-161509

    mTOR Cancer
    PT-88 is a highly selective inhibitor of mTOR (Mammalian target of rapamycin) (IC50=1.2 nM). PT-88 inhibits both mTORC1 and mTORC2 complexes, both of which are active forms of mTOR protein kinases and are closely associated with cell growth, proliferation, and survival. PT-88 can be used to study the role of mTOR in tumorigenesis and development, especially in the study of breast cancer .
    PT-88
  • HY-108697A

    HIF/HIF Prolyl-Hydroxylase Cancer
    (Rac)-PT2399 (Compound 10e), the racemate of PT2399, acts as a potent and specific hypoxia-inducible factor 2a (HIF-2α) inhibitor with an IC50 of 0.01 μM .
    (Rac)-PT2399
  • HY-125840R

    PT2977 (Standard); MK-6482 (Standard)

    HIF/HIF Prolyl-Hydroxylase Reference Standards Cancer
    Belzutifan (Standard) is the analytical standard of Belzutifan. This product is intended for research and analytical applications. Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC) .
    Belzutifan (Standard)
  • HY-137787

    Drug Intermediate Others
    Cyanosafracin B is a starting material for synthesis of Ecteinascidin ET-743 and Phthalascidin Pt-650 .
    Cyanosafracin B
  • HY-W019870A

    Herbicide Neurological Disease
    Glufosinate, a phosphinic acid analogue of glutamic acid, is a herbicide which is converted by plant cells into PT (L-phosphinothricin). Glufosinate exerts neurotoxic activity .
    Glufosinate
  • HY-142956

    Reactive Oxygen Species (ROS) Cancer
    ROS-ERS inducer 1 is a type II ICD (immunogenic cell death) inducer. ROS-ERS inducer 1 is a Pt(II)-N-heterocyclic carbene (Pt(II)-NHC) complex derived from 4,5-diarylimidazole. ROS-ERS inducer 1 successfully induces endoplasmic reticulum stress (ERS) accompanied by reactive oxygen species (ROS) generation and finally lead to the release of damage-associated molecular patterns (DAMPs) in HCC cells. ROS-ERS inducer 1 displays much higher anticancer activities than Cisplatin .
    ROS-ERS inducer 1
  • HY-W019870R

    Herbicide Reference Standards Neurological Disease
    Glufosinate (ammonium) (Standard) is the analytical standard of Glufosinate (ammonium). This product is intended for research and analytical applications. Glufosinate ammonium, a phosphinic acid analogue of glutamic acid, is an herbicide which is converted by plant cells into PT (L-phosphinothricin). Glufosinate ammonium exerts neurotoxic activity .
    Glufosinate ammonium (Standard)
  • HY-P991374

    Tau Protein Neurological Disease
    PNT001 is a human IgG1 monoclonal antibody (mAb) targeting cis-pT231 Tau. PNT001 can be used in Neurodegenerative disorders and Traumatic brain injuries research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    PNT001
  • HY-151883

    Apoptosis MDM-2/p53 Cancer
    APE1-IN-2 (compound AP1) is a Pt(IV) proagent, targeting a critical BER protein, apurinic/apyrimidinic endonuclease 1 (APE1). APE1-IN-2 shows anticancer activity. APE1-IN-2 induces intracellular accumulation of platinum and activates DNA damage response and apoptosis signals .
    APE1-IN-2
  • HY-W112941

    PT(II) Meso-Tetraphenylporphine

    MOFs Others
    Meso- tetraphenylporphyrin - pt(ii) is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
    (meso-Tetraphenylporphinato)platinum
  • HY-179392

    Apoptosis DNA Alkylator/Crosslinker VEGFR PDGFR Cancer
    Sunitinib-platinum(IV) prodrug-1 (Complex A) is a Pt(IV) prodrug based on Cisplatin (HY-17394), and this design aims to enable Pt(IV) to be reduced to active Pt(II) under intracellular reducing conditions, while simultaneously releasing a derivative of Sunitinib (HY-10255A) with tyrosine kinase inhibitor (TKI) activity. Sunitinib-platinum(IV) prodrug-1 exhibits excellent cytotoxicity against renal cell carcinoma (RCC), causing DNA crosslinking and apoptosis. Sunitinib-platinum(IV) prodrug-1 inhibits the VEGFR/PDGFR signaling pathway, suppressing tumor growth and angiogenesis. Sunitinib-platinum(IV) prodrug-1 can be used for research on renal cell carcinoma .
    Sunitinib-platinum(IV) prodrug-1
  • HY-13233B
    Talabostat isomer mesylate
    1 Publications Verification

    Dipeptidyl Peptidase Others
    Talabostat isomer mesylate is an isomer of talabostat mesylate. Talabostat (PT100, Val-boroPro) is a potent, nonselective and orally available dipeptidyl peptidase IV (DPP-IV) inhibitor with a Ki of 0.18 nM.
    Talabostat isomer mesylate
  • HY-100035

    ROCK ERK CDK Apoptosis Cancer
    PT-262 is a potent ROCK inhibitor with an IC50 value of around 5 μM. PT-262 induces the loss of mitochondrial membrane potential and elevates the caspase-3 activation and apoptosis. PT-262 inhibits the ERK and CDC2 phosphorylation via a p53-independent pathway. PT-262 blocks cytoskeleton function and cell migration. PT-262 has anti-cancer activity .
    PT-262
  • HY-W778423

    Dihydroxy Oxaliplatin-PT(IV)

    Drug Intermediate Cancer
    [Pt(DACH)(OH)2(ox)] is a Pt(IV) derivative of Oxaliplatin (HY-17371) with two axial hydroxido ligands, used as a precursor for synthesizing Pt(IV)-HDAC inhibitor prodrugs. [Pt(DACH)(OH)2(ox)] exerts cytotoxic activity against human cancer cells and accumulates in cancer cells for nuclear internalization and nuclear DNA platination. [Pt(DACH)(OH)2(ox)] can be used for the research of lung carcinoma, breast carcinoma, pancreatic carcinoma, colon carcinoma .
    [Pt(DACH)(OH)2(ox)]
  • HY-P10782

    Peptide-Drug Conjugates (PDCs) Cancer
    Pt(IV)-M13 is a BBB-penetrable Platinum (IV) prodrug-perfluoroaryl macrocyclic peptide conjugate. Pt(IV)-M13 is cytotoxic to glioma stem cells and increases uptake of platinum in the brain. Pt(IV)-M13 can be used in the study of glioblastoma .
    Pt(IV)-M13
  • HY-W783446A

    DACH-sulph

    DNA/RNA Synthesis Cancer
    DACH-Pt-SO4 (DACH-sulph) is an anti-tumor agent. DACH-Pt-SO4 inhibits DNA function and cellular proliferation. DACH-Pt-SO4 reduces chloramphenicol acetyltransferase (CAT) expression in repair-deficient cells. DACH-Pt-SO4 can be used for the study of cancer .
    DACH-Pt-SO4
  • HY-136476G

    Drug Intermediate Others
    Pt(II) protoporphyrin IX is a protoporphyrin IX. Protoporphyrin IX is a heterocyclic organic compound, which consists of four pyrrole rings, and is the final intermediate in the heme biosynthetic pathway .
    Pt(II) protoporphyrin IX

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: